Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives

Abstract Medullary thyroid carcinoma (MTC) is a rare type of thyroid malignancy that accounts for approximately 1–2% of all thyroid cancers (TCs). MTC include hereditary and sporadic cases, the former derived from a germline mutation of rearrangement during transfection (RET) proto-oncogene, whereas...

Full description

Bibliographic Details

Published in:	Cell Communication and Signaling
Main Authors:	Ying Zhang, Wei-Hui Zheng, Shi-Hong Zhou, Jia-Lei Gu, Qing Yu, Yi-Zhou Zhu, Yu-Jie Yan, Zhi Zhu, Jin-Biao Shang
Format:	Article
Language:	English
Published:	BMC 2024-09-01
Subjects:	Medullary thyroid carcinoma (MTC) Rearrangement during transfection (RET) Tyrosine kinase inhibitors (TKIs) Targeted therapy
Online Access:	https://doi.org/10.1186/s12964-024-01837-x